A5067800144- Pacific and Southeast Asian Studies
- Hematopoietic Stem Cell Transplantation
- Archaeology and ancient environmental studies
- Maritime and Coastal Archaeology
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- SARS-CoV-2 and COVID-19 Research
- Acute Myeloid Leukemia Research
- COVID-19 Clinical Research Studies
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Pleistocene-Era Hominins and Archaeology
- Head and Neck Cancer Studies
- Immunotherapy and Immune Responses
- Isotope Analysis in Ecology
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Cutaneous lymphoproliferative disorders research
- T-cell and Retrovirus Studies
- Blood groups and transfusion
- HIV/AIDS drug development and treatment
- Chronic Lymphocytic Leukemia Research
- Cytomegalovirus and herpesvirus research
- Advanced Radiotherapy Techniques
- Pneumocystis jirovecii pneumonia detection and treatment
Hôpitaux Universitaires Henri-Mondor
2018-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Université Paris-Est Créteil
2016-2025
Inserm
1986-2025
Institut Mondor de Recherche Biomédicale
2017-2025
Australian National University
2016-2023
Hôpital Albert-Chenevier
2020-2023
Australian Research Council
2022-2023
Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine
2022
Centre for Australian National Biodiversity Research
2022
Acute graft-versus-host disease (aGVHD) represents a challenging complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Despite the intensive pre-clinical research in field of prevention and treatment aGVHD, presence well-established clinical grading system to evaluate human such valid tool is still lacking for evaluation murine aGVHD. Indeed, several scoring systems have been reported, but none them has properly evaluated they all share some limitations:...
Genital chronic graft-versus-host disease (GVHD) is a frequent but underdiagnosed complication of allogeneic stem-cell transplantation impairing quality life. We identified 32 female patients with genital GVHD (cGVHD) who underwent hematopoietic in our center between 2000 and 2010 were followed after specialized gynecological consultation. Pre- posttransplantation clinical data detailed acute cGVHD collected. All received the same local treatment for lesions. At presentation, most complained...
Background Cisplatin-induced hearing loss is frequent and severe. Antioxidants such as sodium thiosulfate (STS) can neutralize the effects of cisplatin. The objective trial was to test efficacy trans-tympanic injections a STS gel prevent cisplatin-induced ototoxicity. Methods Eligible participants were newly diagnosed patients with stage III or IV squamous cell carcinoma mouth, oropharynx, hypopharynx, larynx scheduled be treated by concurrent chemoradiation (CCR). Patients asymmetric not...
Targeting immune checkpoints that inhibit antitumor responses has emerged as a powerful new approach to treat cancer. We recently showed blocking the tumor necrosis factor receptor-type 2 (TNFR2) pathway induces complete loss of protective function regulatory T cells (Tregs) in model graft-versus-host disease (GVHD) prevention relies on Treg-based cell therapy. Here, we tested possibility amplifying response by targeting TNFR2 relapse following hematopoietic stem-cell transplantation,...
Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought evaluate the dynamics of response BNT162b2 mRNA vaccine in HSCT recipients. systematically proposed vaccination with gave a third dose those showing titers IgG(S-RBD) below 4160 AU/mL 1 month following second dose. then quantified anti-SARS-CoV-2 antibodies 133 these (88 after two 45 three doses) 6 months first Mean titer was significantly...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. Primary analysis of phase III randomized AATT study showed younger patients with peripheral T-cell lymphoma (PTCL)...